NovoCure (NVCR) Liabilities and Shareholders Equity (2014 - 2026)

NovoCure has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $787.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $787.9 million, down 36.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 billion (down 14.71% YoY), and the FY2025 annual result was $804.3 million, down 35.18% from the prior year.
• Liabilities and Shareholders Equity came in at $787.9 million for Q1 2026 at NovoCure, down from $804.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q3 2025 to a low of $787.9 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2022), against an average of $1.1 billion.
• Across the five-year window, Liabilities and Shareholders Equity advanced 11.39% in 2025 and sank 36.91% in 2026, its largest moves.
• NovoCure's Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then declined by 3.82% to $1.1 billion in 2023, then increased by 8.26% to $1.2 billion in 2024, then slumped by 35.18% to $804.3 million in 2025, then declined by 2.04% to $787.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $787.9 million (Q1 2026), $804.3 million (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.